文献速递肿瘤 PET/CT

双示踪剂PSMA/FDG PET/CT在前列腺切除术后生化复发且常规影像阴性患者中的病灶检测与风险分层

Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-20

这项单中心回顾性研究纳入58例前列腺切除术后生化复发且常规影像阴性的患者,评估配对68Ga-PSMA-11与18F-FDG PET/CT的病灶检出模式和风险分层价值。21例(36.2%)任一示踪剂阳性,总体双示踪剂PET阳性率随PSA分层和预设风险特征数量增加而升高(趋势P均<0.001)。在PET可检出病变的患者中,FDG高摄取病变与不良临床病理特征相关。

要点

  • 58例中21例(36.2%)双示踪剂PET任一阳性,阳性率随PSA和风险特征增加而升高。
  • FDG高摄取病变与病理分期≥pT3、N1、3年内复发及PSA倍增时间≤6个月相关。
  • 双示踪剂PET可揭示常规影像阴性生化复发患者的病变异质性,辅助风险分层。

核心结论

  • 配对68Ga-PSMA-11与18F-FDG PET/CT在前列腺切除术后生化复发且常规影像阴性患者中可揭示病灶检测之外的异质性。
  • 在PET可检出病变的患者中,FDG高摄取病变富集了不良临床病理特征。
  • 公共单细胞转录组分析为双示踪剂表型差异提供了假说生成性的生物学背景。

研究设计与样本

  • 回顾性单中心研究,纳入前列腺切除术后生化复发且PET/CT前1个月内常规影像阴性的患者。
  • 患者接受配对68Ga-PSMA-11与18F-FDG PET/CT,两次检查间隔在14天内。
  • 总体双示踪剂PET阳性定义为任一示踪剂至少1个阳性病灶。
  • 在任一示踪剂PET可检出病变的患者中,表型分为PSMA+/FDG-、PSMA+/FDG+或PSMA-/FDG+。
  • 分析公共单细胞RNA测序数据以评估FOLH1表达与糖酵解活性的关系。

主要发现

  • 58例患者中21例(36.2%)任一示踪剂至少1个阳性病灶。
  • 总体双示踪剂PET阳性率随PSA分层升高(趋势P<0.001)。
  • 总体双示踪剂PET阳性率随预设风险特征数量增加而升高(趋势P<0.001)。
  • 年龄较大和PET时PSA较高与总体双示踪剂PET阳性独立相关。
  • 在PET可检出病变的患者中,FDG高摄取病变与病理分期≥pT3、病理N1、根治性前列腺切除术后3年内复发及PSA倍增时间≤6个月相关。

临床怎么用

  • 对于前列腺切除术后生化复发且常规影像阴性的患者,可考虑配对68Ga-PSMA-11与18F-FDG PET/CT以检测病灶并评估FDG高摄取所提示的不良风险特征。

局限性

  • 回顾性单中心设计。
  • 样本量58例。
  • 公共单细胞转录组分析结果仅为假说生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate lesion detection patterns and the risk-stratification value of paired 68Ga-PSMA-11 and 18F-FDG PET/CT in patients with post-prostatectomy biochemical recurrence (BCR) and negative conventional imaging, and to explore the hypothesis-generating biological context of dual-tracer phenotypes using public single-cell transcriptomic data. METHODS: This retrospective single-center study included patients with post-prostatectomy BCR who underwent paired 68Ga-PSMA-11 and 18F-FDG PET/CT within 14 days and had negative conventional imaging within 1 month before PET/CT. Overall dual-tracer PET positivity was defined as at least 1 positive lesion on either tracer. Among patients with PET-detectable disease on either tracer, phenotypes were classified as PSMA+/FDG-, PSMA+/FDG+, or PSMA-/FDG+. Public single-cell RNA sequencing data were analyzed to assess the relationship between FOLH1 expression and glycolytic activity. RESULTS: Among 58 included patients, 21 (36.2%) had at least one positive lesion on either tracer. Overall dual-tracer PET positivity increased across PSA strata and with a greater number of prespecified risk features (both P for trend < 0.001). Older age and higher PSA at PET were independently associated with overall dual-tracer PET positivity. Among patients with PET-detectable disease on either tracer, FDG-avid disease was associated with pathologic stage ≥pT3, pathologic N1 disease, recurrence within 3 years after radical prostatectomy, and PSA doubling time ≤ 6 months. In the public single-cell cohort, FOLH1 expression and glycolytic activity showed only a weak association. CONCLUSION: Paired 68Ga-PSMA-11 and 18F-FDG PET/CT revealed heterogeneity beyond lesion detection in patients with post-prostatectomy BCR and negative conventional imaging. Among patients with PET-detectable disease on either tracer, FDG-avid disease was enriched for adverse clinicopathologic features, and public single-cell transcriptomic analysis provided hypothesis-generating biological context for divergent dual-tracer phenotypes.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bian L, Huang X, Zhu B, et al. Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging. Eur J Nucl Med Mol Imaging. 2026. PMID: 42474501. doi:10.1007/s00259-026-08089-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。